Headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom, the healthtech’s core aim is to detect cancer early, when it can be cured, and its technology is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early.
According to reports, GRAIL uses next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA.
The company’s strategy is to partner with more health & life insurers to offer early detection services, cutting cancer risk, treatment costs and providing better outcomes for patients. Currently, GRAIL has strategic partnerships with Munich Re, M Financial and John Hancock.
Transforming cancer care and cancer mortality
Fortune evaluates companies based on measurable social impact, business results, and innovation. GRAIL’s inclusion is attributed to its transformative efforts in reshaping cancer care and altering the trajectory of cancer mortality. The groundbreaking Galleri® multi-cancer early detection (MCED) test developed by GRAIL is at the forefront of this commendation. This pioneering screening test can identify a signal common to over 50 cancer types and predict the associated tissue or organ.
The true power of MCED, according to GRAIL, lies in its ability to detect and localise shared cancer signals. This provides physicians with crucial information to guide diagnostic testing, offering a potential breakthrough in early cancer detection.
“Being included on Fortune’s Change the World List is an honour that recognises our dedication to GRAIL’s mission – to detect cancer early, when it can be cured – and the work of everyone at GRAIL to meaningfully make a difference in cancer,” said Bob Ragusa, chief executive officer at GRAIL.
He added: “Our goal is to redefine the status quo of cancer detection and our teams continue to work together to bring about the public health change needed to dramatically improve cancer outcomes.”
